This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).
Achaogen's Plazomicin Gets Breakthrough Therapy Designation
by Zacks Equity Research
Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae.
Catalyst Pharmaceuticals Focuses on Development of Firdapse
by Zacks Equity Research
We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX) on May 22.
Calithera Biosciences (CALA) Jumps: Stock Moves 17% Higher
by Zacks Equity Research
Calithera Biosciences, Inc. (CALA) shares rise over 17% in the last trading session.
Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.
Alexion's (ALXN) Strensiq Results Positive in Long-Term Study
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society (ECTS) Congress in Austria.
Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Kamada Ltd. (KMDA) reported adjusted loss of 11 cents in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 3 cents.
Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now
by Zacks Equity Research
On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI).
Minerva (NERV) Provides Phase III Development Strategy for MIN-101
by Zacks Equity Research
Minerva Neurosciences, Inc. (NERV) announced plans for its phase III and phase IV clinical development of pipeline candidate MIN-101.
Ionis (IONS) Stock Falls Despite Positive Inotersen Data
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.